GLIMPCE: Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 4
- 主要终点
- Determining the Threshold
研究概览
简要总结
In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor progression after radiotherapy and/or chemotherapy treatment.
An issue with the current treatment for patients with a brain tumor, is the inability to detect tumor progression early. An abnormality is seen on MRI scans taken shortly after treatment with radiotherapy in about 30% of patients.
This abnormality may be a sign that radiotherapy treatment has worked well and will disappear on its own after a while. However, an abnormality can also be a sign of active tumor tissue. Then it shows that the treatment has not worked well enough. When there is active tumor tissue, this is called 'tumor progression'. When there is an abnormality that disappears on its own after a while, there is no active tumor tissue. This is called 'pseudoprogression'.
Currently, there are two options to determine whether tumor progression or pseudoprogression has taken place: Do another brain surgery to see if the abnormality contains active tumor tissue or wait and have regular MRI scans until it is clear whether the abnormality goes away on its own.
Amide proton transfer weighted chemical exchange saturation transfer (APTw-CEST) imaging is a new MRI technique in which investigators can produce images that show the accumulation of protein. APTw-CEST has previously been shown to be able to distinguish tumor progression from pseudoprogression earlier than current standard MRI scans. However, these previous studies have drawbacks: they were either done with a small group of patients in 1 hospital, or with a 7 Tesla MRI scanner, a rare type of scanner not standard in hospitals, or done in animal models.
In this research project the investigators now want to prepare APTw-CEST for standard patient care for patients with glioblastoma in the Netherlands so that in the future APTw-CEST can be included as a standard scan during treatment. The investigators are doing this by introducing APTw-CEST MRI on the clinical MRI scanners of four different hospitals. Ultimately, the investigators want to use this to create national guidelines for measuring and viewing APTw-CEST MRI images for early detection of tumor progression.
详细描述
Rationale:
A major issue with glioblastoma treatment is the occurrence of contrast enhancement after treatment with radiotherapy or chemoradiotherapy. This enhancement can be due to more tumor growth; called true progression. It can also be due to treatment-related effects; called pseudoprogression. Amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is a technique that indirectly images proteins and peptides in a tissue. Because these molecules are overexpressed in tumor tissue, APTw-CEST MRI has been shown to be good at distinguishing between true progression and pseudoprogression, which is important as they require vastly different responses. This technique shows promise to become an important biomarker in glioblastoma treatment, how-ever it currently lacks standardization, as studies are generally done in one center on MRI machines of one vendor.
This multi-center study will make APTw-CEST MRI a clinically usable biomarker for the detection of tumor progression in glioblastoma patients by providing acquisition and post-processing recommendations, as well as a threshold on APTw-CEST images that would allow a clinician to accurately distinguish between pseudoprogression and true progression, regard-less of where the images were acquired and with which system.
The underlying processes that make APTw-CEST a reliable biomarker for glioblastoma treatment response evaluation are not clearly known. Using other advanced MRI techniques (diffusion, perfusion) and O-(2-[18F]fluoroethyl-)-L-tyrosine Positron Emission Tomography (FET-PET), and correlating these images with the APTw-CEST images will give a better insight into these processes.
Primary Objective: Determine the optimal threshold on APTw-CEST images in a multi-center (4 academic institutes) multi-vendor (Philips, Siemens and GE) clinical trial, to distinguish tumor progression from treatment-related effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of glioblastoma based on histopathological or molecular analysis of biopsy after surgery, or suspected of glioblastoma based on medical imaging.
- •Scheduled to undergo radiotherapy or combined chemo-and radiotherapy
- •18 years and older
- •Able to give informed consent.
- •Patient will undergo clinically indicated MRIs
排除标准
- •Not able to give informed consent
- •Contraindication for MRI
- •Brain pathology affecting CEST contrast, such as recent stroke or earlier cranial radiotherapy, as determined by the principal investigators (PIs)
研究组 & 干预措施
Extended MRI
The MRI protocol for every clinical MRI scan taken in follow-up is extended with 15 minutes.
干预措施: Extended MRI (Diagnostic Test)
结局指标
主要结局
Determining the Threshold
时间窗: Until 1 year after the first MRI scan with the additional APTw-CEST added
Determine the optimal threshold on APTw-CEST images in a multi-center (4 aca-demic institutes) multi-vendor (Philips, Siemens and GE) clinical trial, to distinguish tumor progression from treatment-related effects.
次要结局
- Correlations with other MRI and PET scans.(Up until 1 year from the date of the first MRI scan with added APTw-CEST)
研究者
Esther Warnert
Assistant Professor
Erasmus Medical Center